The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure
暂无分享,去创建一个
Joseph Horowitz | Yossi Chait | Michael J Germain | Christopher V Hollot | C. Hollot | Y. Chait | J. Horowitz | R. Thadhani | M. Germain | E. Ankers | Ravi I Thadhani | Sahir Kalim | Sahir Kalim | Elizabeth D Ankers
[1] J. Widness,et al. A ‘bottom‐up’ approach for endo‐PK/PD analysis , 2006, Biopharmaceutics & drug disposition.
[2] Saul Nurko,et al. Anemia in chronic kidney disease: causes, diagnosis, treatment. , 2006, Cleveland Clinic journal of medicine.
[3] H. Uno,et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.
[4] P. Aljama,et al. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. , 2008, Kidney international. Supplement.
[5] S. Fukuhara,et al. Time-Dependent Resistance to Erythropoiesis-Stimulating Agent and Mortality in Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study , 2013, Nephron Clinical Practice.
[6] Huiman Barnhart,et al. Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.
[7] K. Otsuka,et al. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study , 2013, International Urology and Nephrology.
[8] A. Collins,et al. Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics , 2013, BMC Nephrology.
[9] G. Kaysen,et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] J. Brockmöller,et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. , 1992, British journal of clinical pharmacology.
[11] Grace H. Lee,et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] Marcello Tonelli,et al. Cohort studies: marching forward. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[13] R. Garrick. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .
[14] S. Fishbane,et al. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.
[15] Grace H. Lee,et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] D. Mould,et al. Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model , 2015, Journal of clinical pharmacology.
[17] M. Wolf,et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.
[18] Wojciech Krzyzanski,et al. Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[19] M. Brier,et al. Application of fuzzy logic to predicting erythropoietic response in hemodialysis patients , 2008 .
[20] W. Winkelmayer,et al. Greater Epoetin alfa (EPO) doses and short‐term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL , 2009, Pharmacoepidemiology and drug safety.
[21] C. Stehman-Breen,et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[22] R. Califf,et al. Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease , 2013, American Journal of Nephrology.
[23] M. Hernán,et al. The effect of epoetin dose on hematocrit. , 2008, Kidney international.
[24] Avid,et al. THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .
[25] M. Brookhart,et al. Confounding and control of confounding in nonexperimental studies of medications in patients with CKD. , 2012, Advances in chronic kidney disease.
[26] A. Berg,et al. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[27] George A Kaysen,et al. Challenging the validity of the EPO index. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] Joseph Horowitz,et al. Control-Relevant Erythropoiesis Modeling in End-Stage Renal Disease , 2014, IEEE Transactions on Biomedical Engineering.
[29] Chul-woo Yang,et al. Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis , 2012, Hemodialysis international. International Symposium on Home Hemodialysis.
[30] R. Bigazzi,et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.